Nanoscope Therapeutics to Present at the Next Generation Ophthalmic Drug Delivery Summit

Nanoscope Therapeutics to Present at the Next Generation Ophthalmic Drug Delivery Summit

DALLAS, Jan. 19, 2023  — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Dr. Samarendra Mohanty, President and Chief Scientific Officer of Nanoscope Therapeutics, will give a presentation titled “Pioneering Laser-Targeted Optical Delivery of Therapeutics to the Eye” and participate in a panel discussion at the Next Generation Ophthalmic Drug Delivery Summit, taking place January 24-26, 2023 in San Francisco.

Details for the presentation and panel are as follows:

Pioneering Laser-Targeted Optical Delivery of Therapeutics to the Eye
Date and Time: Thursday, January 26, 2023; 11:45 a.m. PT
Location: Hyatt Centric Fisherman’s Wharf

In his presentation, Dr. Mohanty will discuss the application of laser-targeted optical delivery as a therapeutic platform, and he will detail Nanoscope’s proof-of-concept to deliver genes and other molecules.

Panel Discussion: What is the Ideal System to Test Durable Ophthalmic Therapies? Discussing Desired
Attributes for a Benchmark System
Date and Time: Thursday, January 26, 2023; 9:15 a.m. PT
Location: Hyatt Centric Fisherman’s Wharf

About Nanoscope Therapeutics Inc.

Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top-line data expected Q1 2023. The company has also fully enrolled a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA Fast Track designation for RP and FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

On January 19, 2023   /   Nanoscope Press Release, Home Page  
Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186

  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Samar obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from the National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs an international conference on optogenetics. He is the winner of a 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.